• 1
    Ferlay J,Bray F,Pisani P,Parkin DM. Globocan 2002: Cancer incidence, mortality and prevalence worldwide. IARC Cancerbase No. 5, version 2.0. Lyon: IARC, 2004.
  • 2
    Kim JJ,Wright TC,Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst 2005; 97: 88895.
  • 3
    Australian Government–Department of Health and Ageing. Pap test register. 2007. Available at (accessed December 6, 2007).
  • 4
    Rebolj M,van Ballegooijen M,Berkers LM,Habbema D. Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer 2007; 120: 80612.
  • 5
    Cancer Registry Finland. Screening for cervical cancer in 2005. 2007. Available at (accessed December 5, 2007).
  • 6
    NHS Cancer Screening Programmes. Annual Review 2006: NHS Cervical Screening Programme. 2007.
  • 7
    Nygard JF,Skare GB,Thoresen SO. The cervical cancer screening programme in Norway, 1992–2000: changes in Pap smear coverage and incidence of cervical cancer. J Med Screen 2002; 9: 8691.
  • 8
    BC Cancer Agency–Cervical Cancer Screening Program, 2004 Annual Report. 2004. Available at (accessed December 6, 2007).
  • 9
    Bos AB,van Ballegooijen M,van Oortmarssen GJ,van Marle ME,Habbema JD,Lynge E. Non-progression of cervical intraepithelial neoplasia estimated from population-screening data. Br J Cancer 1997; 75: 12430.
  • 10
    Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12: 18692.
  • 11
    Berkers LM,van Ballegooijen M,van Kemenade FJ,Rebolj M,Essink-Bot ML,Helmerhorst TJ,Habbema JD. [The 1996 revision of the Dutch cervical cancer screening programme: increased coverage, fewer repeat smears and less opportunistic screening] Herziening bevolkingsonderzoek op baarmoederhalskanker 1996: hogere dekkingsgraad, minder herhalingsuitstrijkjes en minder opportunistische screening. Ned Tijdschr Geneeskd 2007; 151: 128894.
  • 12
    Dutch Association of Pathologists. CISOE-A in pictures (in Dutch). CD-Rom. In: HanselaarAGJM, ed. Nijmegen, The Netherlands: University Medical center Nijmegen, 1997.
  • 13
    Bulk S,Van Kemenade FJ,Rozendaal L,Meijer CJ. The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 2004; 57: 38893.
  • 14
    NHSCSP, Achievable standards, benchmarks for reporting, and criteria for evaluating cervical cytopathology. NHS Cancer Screening Programmes, 2000.
  • 15
    Solomon D,Davey D,Kurman R,Moriarty A,O'Connor D,Prey M,Raab S,Sherman M,Wilbur D,Wright TJr,Young N,Forum Group M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: 211419.
  • 16
    Giard RW,Hermans J,Doornewaard H. National results of cervix cytology diagnosis in 1992; efficacy of screening could be improved (in Dutch). Ned Tijdschr Geneeskd 1994; 138: 132530.
  • 17
    Bos AB,van Ballegooijen M,van den Akker-vanMarle ME,Habbema JD. Less pap-2 results (‘minor abnormalities’) in the population screening for cervical cancer since the introduction of new guidelines in 1996 (in Dutch). Ned Tijdschr Geneeskd 2002; 146: 158690.
  • 18
    Vooijs GP. Recommendations in aberrant findings of cytological studies of the cervix uteri (in Dutch). Ned Tijdschr Geneeskd 1987; 131: 16623.
  • 19
    Prismant. Dutch Network and National Database for Pathology (PALGA): results of retrieval action of cervix uteri tests until 31-03-2007. Utrecht: Prismant, 2007.
  • 20
    PALGA. Description of the PALGA system and computer network, in Dutch. Utrecht, The Netherlands, 2004. Available at
  • 21
    Brandt PAvd,Schouten LJ,Goldbohm RA,Dorant E,Hunen PM. Development of a record linkage protocol for use in the Dutch Cancer Registry for Epidemiological Research. Int J Epidemiol 1990; 19: 5538.
  • 22
    Akker-van Marle MEvd,van Ballegooijen M,Habbema JD. Low risk of cervical cancer during a long period after negative screening in the Netherlands. Br J Cancer 2003; 88: 10547.
  • 23
    Helmerhorst TJ,Wijnen JA. Guidelines for the cervical cancer screening programme (In Dutch). Ned Tijdschr Obstet Gynaecol 1998; 111: 2645.
  • 24
    Harrell FE. Regression modelling strategies with applications to linear models, logistic regression, and survival analysis. New York: Springer, 2001.
  • 25
    Dutch Comprehensive Cancer Centres. Cancer Registry Online: Core indicators, Dutch. Available at (accessed 2006–2008).
  • 26
    Benard VB,Eheman CR,Lawson HW,Blackman DK,Anderson C,Helsel W,Thames SF,Lee NC. Cervical screening in the National Breast and Cervical Cancer Early Detection Program, 1995–2001. Obstet Gynecol 2004; 103: 56471.
  • 27
    Government Statistical Office, The Information Centre, Cervical Screening Programme, 2005-06, England, 2007.
  • 28
    Hewitt M,Devesa SS,Breen N. Cervical cancer screening among U.S. women: analyses of the 2000 National Health Interview Survey. Prev Med 2004; 39: 2708.
  • 29
    Scott DR,Hagmar B,Maddox P,Hjerpe A,Dillner J,Cuzick J,Sherman ME,Stoler MH,Kurman RJ,Kiviat NB,Manos MM,Schiffman M. Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom. Cancer 2002; 96: 1420.
  • 30
    van Kemenade FJ,Wiersma T,Helmerhorst TJ. [New version of the pathology practice guideline for cervical cytology: sharpened criteria for adequacy; expanded use of new techniques] Nieuwe versie van de pathologiepraktijkrichtlijn voor cervixcytologisch onderzoek: criteria voor adequaatheid aangescherpt; gebruik van nieuwe technieken verruimd. Ned Tijdschr Geneeskd 2007; 151: 12836.
  • 31
    Hanselaar AG. Criteria for organized cervical screening programs. Special emphasis on The Netherlands program. Acta Cytol 2002; 46: 61929.
  • 32
    Bulkmans N,Berkhof J,Rozendaal L,van Kemenade F,Boeke A,Bulk S,Voorhorst F,Verheijen R,van Groningen K,Boon M,Ruitinga W,van Ballegooijen M, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 176472.
  • 33
    Naucler P,Ryd W,Tornberg S,Strand A,Wadell G,Elfgren K,Radberg T,Strander B,Forslund O,Hansson BG,Rylander E,Dillner J. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 158997.
  • 34
    Davies P,Arbyn M,Dillner J,Kitchener HC,Meijer CJ,Ronco G,Hakama M. A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. Int J Cancer 2006; 118: 7916.